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Abstract
Background: An association between a common deletion comprising the late cornified envelope LCE3B and
LCE3C genes (LCE3C_LCE3B-del) and Psoriasis (Ps) has been reported. The expression of these LCE genes was
induced after skin barrier disruption and was also strong in psoriatic lesions. The damage to the skin barrier could
trigger an epidermal response that includes the expression of genes involved in the formation of skin barrier.
Methods: We determined the LCE3C_LCE3B-del genotype in 405 Ps patients and 400 healthy controls from a
Northern Spain region (Asturias). These patients and controls were also genotyped for the rs4112788 single
nucleotide polymorphism, in strong linkage disequilibrium with the LCE3C_B cluster. The LCE3B and LCE3C gene
variant was determined in the patients through SSCA, DHPLC, and direct sequencing.
Results: Allele and genotype frequencies did not differ between patients and controls for the rs4112788 and
LCE3C_LCE3B-del polymorphisms. However, del/del homozygotes were significantly higher among patients with
chronic plaque type Ps who did not develop arthritis (p = 0.03; OR = 1.4; 95%CI = 1.03-1.92). The analysis of the
coding sequence of LCE3B and LCE3C in the patients who had at least one copy of this showed that only one
patient has a no previously reported LCE3B variant (R68C).
Conclusion: Our work suggested that homozygosity for a common LCE3C_LCE3B deletion contributes to the risk
of developing chronic plaque type Ps without psoriatic arthritis. Our work confirmed previous reports that
described an association of this marker with only skin manifestations, and supported the concept of different
genetic risk factors contributing to skin and joint disease.
Background
Psoriasis (Ps) is a chronic hyperproliferative inflamma-
tory disease of the skin that affects approximately 2% of
individuals [1]. Ps is characterized by an abnormal kera-
tinocyte proliferation and differentiation, and the infil-
tration of immunocompetent cells in the epidermis and
dermis [2]. Psoriatic arthritis (PsA) is a chronic inflam-
matory joint disease which occurs in 7-42% of Ps
patients [3]. Ps susceptibility involves environmental and
genetic factors [4]. The genetic component is partly
explained by its association to the HLA-Cw6 allele, that
defines the PSOR1 locus on chromosome 6p21 [5,6].
Genome-wide association studies (GWA) and family-
based studies have identified other Ps associated genes,
and some of them encode proteins involved in the
immune response and expressed in keratinocytes and T
cells [7-10].
Copy number variants (CNVs) are an important
source of genetic variability, and contribute to the sus-
ceptibility to several diseases [11]. A candidate gene
approach identified a higher copy number of the beta-
defensin cluster as a risk factor for Ps, and a recent gen-
ome-wide CNV analysis identified the association of Ps
with a deletion comprising the LCE3B and LCE3C genes
(LCE3C_LCE3B-del) [9,12]. These genes encode mem-
bers of the late cornified envelope (LCE), and are in the
region that contains the PSORS4 locus on chromosome
1q21 [13,14]. The mRNA for several LCE3 genes was
absent in normal skin, but its expression was induced
after skin barrier disruption and was also strong in psor-
iatic lesions [9]. In this way, the damage to the skin bar-
rier could trigger an epidermal response that includes
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skin barrier, such as those in the LCE cluster. The
impaired response in individuals homozygous for the
LCE3C_LCE3B-del could explain the higher risk for Ps
conferred by this genotype. The reported lack of asso-
ciation between the LCE3C_LCE3B-del and psoriatic
arthritis suggested that this was a risk factor for only
skin disease, supporting the concept that different
genetic factors contributed to skin disease and joint
manifestations [15,16].
Here, we report the results of a case-control study for
the association between the LCE3C_LCE3B-del and Ps.
In addition, we searched for DNA variants in the coding
sequences of LCE3C and LC3B in Ps patients.
Methods
Patients and controls
All the patients and controls were Spanish Caucasians
from the region of Asturias (Northern Spain, total popu-
lation 1 million). A total of 405 non-related patients with
Ps (mean age 47 ± 16 years; 54% men) were recruited by
Dermatologists from Hospital Universitario Central
Asturias (HUCA) and Hospital A. Buylla-Mieres. Ps was
diagnosed based on clinical findings, and the Psoriasis
Area and Severity Index (PASI) was determined. Patients
who were diagnosed with arthritis prior to Ps were not
included in the study. The disease was considered as
severe in patients with a PASI score = 10 [17]. Patients
were considered to have “early onset“ psoriasis if the
onset of the disease was at any age ≤ 40 years, and “late
onset“ psoriasis if the onset was > 40 years. Patients were
considered to have “familial“ psoriasis if they had at least
one first- or second-degree relative affected by the condi-
tion. Patients with PsA were assessed by a rheumatologist
according to the criteria of Moll and Wright [18]. All the
patients were followed for >2 years after psoriasis was
diagnosed (mean follow-up, 17 ± 14 years). Table 1 sum-
marizes the main characteristics of the patients.
The control group comprised 400 non-related healthy
individuals (mean age 49 ± 16 years; range 18-85 years;
55% men) recruited through the Dermatology Depart-
ment (Hospital staff and healthy spouses of patients)
and the HUCA-Blood Bank. The study was approved by
the Ethical Committee of HUCA, and all the individuals
gave their informed consent to participate.
LCE3C_LCE3B-del genotyping
We determined the LCE3C_LCE3B-del genotype follow-
ing a three-primer polymerase chain reaction (PCR)
assay, as reported [9]. Genomic DNA from patients and
controls was PCR-amplified in a single tube containing
each of three primers: LCE3F (forward), LCE3CR
(reverse), and LCE3CR2D (reverse). Ten μl of each reac-
tion were electrophoresed on 2% agarose gels, and the
non-deletion allele visualized as a fragment of 240 bp
(LCE3CF-LCE3CR product), and the deletion as a frag-
ment of 199 bp (LCE3CF-LCE3CR2D product).
SNP rs412788 genotyping
SNP rs4112788 (T/C) was genotyped in patients and
controls through restriction enzyme digestion of a PCR
fragment generated with primers Fwd: 5’GTAGAGAC-
TAACCATATAACATGTGG (forward) and Rvs:
5’GAAAACCTTTAGACTACAATTAAAAGC (reverse)
(PCR annealing, 55°C). The last nucleotide in Rvs has a
mismatch to create a site for the restriction enzyme
MspI on PCR fragments with the C allele. After diges-
tion with this enzyme and electrophoresis on 3% agarose
gels, alleles were visualized as bands of 215 bp (T) or
190 + 25 bp (C).
A total of 150 patients and 150 controls (representing
at least 50 of the three PCR-RFLP genotypes) were also
genotyped with a custom Taqman assay for SNP
rs4112788 (assay id C_31910050_10) in a real time PCR
Step One (ABI).
To determine the accuracy of the two genotyping
methods we sequenced 20 individuals with each of the
Table 1 Main characteristics of the 405 patients with
Psoriasis
Gender (male/female) 210 (54%)/195(46%)
Mean age (years ± SD)* 47 ± 16
Type of psoriasis
Vulgaris 324 (80%)
Palmoplantar 49 (12%)
Guttate 16 (4%)
other 16 (4%)
Cw6+ 158 (39%)
Affected relatives
(familial Ps)
219 (54%)
Early-onset psoriasis
# 243 (60%)
Mean age (years ± SD)* 34 ± 14
Cw6+ 124 (51%)
Late-onset psoriasis
# 162 (40%)
Mean age (years ± SD)* 59 ± 9
Cw6+ 34 (21%)
Non-severe Ps (PASI < 10)* 243 (60%)
Severe Ps (PASI ≥ 10)* 162 (40%)
Arthritis 89 (22%)
Non-Arthritis 316 (78%)
#Early onset psoriasis, age ≤40 years; Late onset psoriasis, age>40 years.
*SD, standard deviation; PASI, Psoriasis Area and Severity Index.
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primers Fwd (see above) and 5’ GACTCTCCAAGGGA-
CATTTTTTGT (reverse) (annealing at 56°C), and both
strands were sequenced.
LCE3B/3C mutation screening
We amplified the LCE3B and LCE3C coding sequences in
the patients with primers designated from the reference
sequences http://www.ensembl.org; ENSG00000187238
for LCE3B; ENSG00000187238 for LCE3C). The full tran-
scripts encode proteins of 96 amino acids are contained in
single exons. The LCE3B fragment was 422 bp long and
was amplified with primers GGGCTTCATAAAAC-
CATTTGTAGAG (forward) and TTTCCTCTAAAGT-
CGCTTGTCTCA (reverse) (annealing, 63°C). The LCE3C
was a 448 bp fragment amplified with primers GGTCTG-
AGGGTTCTGTGCTCA (forward) and TCTGGAAAAG-
CATGCATCAGG (reverse) (annealing, 62°C).
To search for DNA variants, a total of 45 LCE3B and
LCE3C fragments (corresponding to 15 ins/ins patients
and 15 ins/del patients) were sequenced. PCR fragments
from all the patients were also subjected to single strand
conformation analysis (SSCA), and fragments with atypi-
cal SSCA electrophoretic patterns were sequenced to
characterize the nucleotide changes [19]. These PCR
fragments were also subjected to Denaturing High Per-
formance Liquid Chromatography (DHPLC) in a Varian
Helix System and with a linear binary gradient created
with buffers Varian Helix A (triethylammonium amine -
TEAA) and B (TEAA+25% acetonitrile; http://www.var-
ianinc.org), and the nucleotide changes responsible for
the different elution profiles were identified by sequen-
cing the corresponding PCR fragments. The DHPLC
elution temperatures and buffer gradients for the PCR
fragments were calculated with the DHPLC Melt Pro-
gram http://insertion.stanford.edu/melt.html, and are
available upon request to the corresponding author.
Statistical analysis
Data management and statistical analysis were carried
out using SPSS for windows (release 15.0; SPSS, Inc).
Differences of the allele frequencies between the groups
were assessed using the c
2 test. Odds ratios (OR) and
their 95% confidence intervals (CI) values were also cal-
culated. The Student’s t test was used to compare the
quantitative data between the groups. A p < 0.05 was
considered as statistically significant. The power of the
study for each frequency comparison was calculated
online http://statpages.org/proppowr.html.
Results
LCE3C_3B del frequencies
We determined the genotype for the common
LCE3C_LCE3B CNV in 405 Ps patients and 400 con-
trols (Figure 1). Genotype and allele frequencies for the
LCE3C_LCE3B-del in patients and controls are summar-
ized in table 2. The observed genotype frequencies did
n o td i f f e rf r o mt h o s ee x p e c t ed under the Hardy-Wein-
berg equilibrium. We did not find significant differences
for the genotype and allele frequencies between the con-
trols and total patients. The del/del frequency was
h i g h e ra m o n gp a t i e n t sw i t hP sv u l g a r i s( n=3 2 4 )c o m -
pared to controls (42% vs. 36%) although the difference
did not reach statistical significance (p = 0.08; OR =
1.30, 95CI = 0.96-1.76).
Because a previous study reported a negative associa-
tion between the LCE3C_LCE3B-del and psoriatic
arthritis, we compared the genotype frequencies
between controls and patients who did not develop
arthritis (n = 274). The frequency of del/del was signifi-
cantly higher in this group compared to controls (44%
vs. 36%; p = 0.03; OR = 1.4 (1.03-1.92). However, the
number of patients/controls was insufficient to reach a
power of 80. At a significance level of p = 0.05, with
del/del frequencies of 0.36 in controls and 0.44 in
Figure 1 PCR-RFLP genotypes of rs4112788 (right) and LCE3B_3C ins/del genotypes (right). The rs4112788 alleles were visualized as
bands of 215 bp (T) and 190 + 25 bp (C). The LCE3B_3C insertion and deletion alleles were visualized as PCR fragments of 240 bp and 199 bp.
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1,154 controls and 938 patients should be genotyped to
reach a power of 80 (% chance of detecting).
SNP rs4112788 genotype frequencies
SNP rs4112788 in the LCE3D gene was genotyped in all
the patients and controls through PCR-RFLP (Figure 1).
This polymorphism maps approximately 4.5 Kb centro-
meric to the LCE3C_LCE3B-del, and allele C has been
reported in almost complete linkage disequilibrium (LD)
with the deletion. In agreement with this, all our
patients and controls who were homozygous for the
deletion were also rs4112788 CC, while all the non-dele-
tion homozygotes were also TT. All but two ins/del
individuals were also CT (one patient and one control
were CC). To determine the accuracy of the PCR-RFLP
method, we first sequenced 60 individuals, 20 each of
the three genotypes. We confirmed the genotype in all
the 60 samples, and we also found a complete disequili-
brium between rs4112788 and rs4112787 (T/C), a SNP
located 49 bp 3’ to rs4112788. A total of 100 patients
and 100 controls were also genotyped with a custom
T a q m a na s s a y( F i g u r e2 ) .W eo n l yf o u n do n ed i s c r e -
pancy between the RFLP and Taqman methods: one
patient genotyped as TC with the PCR-RFLP method
was CC according to the Taqman assay, and sequencing
confirmed the RFLP genotype. Thus, the accuracy of
our PCR-RFLP genotyping method should be almost
complete.
Mutation analysis of LCE3B and LCE3C
We searched for DNA variants in the LCE3B and
LCE3C coding sequences in the patients. After electro-
phoresis of the PCRs, a band was only visible in the 353
patients with at least one copy of LCE3C_LCE3B. This
result confirmed the absence of the two LCE3C_LCE3B
copies in the 149 patients who were genotyped as
homozygotes for the deletion. The sequencing of 45
chromosomes (15 ins/ins and 15 ins/del patients)
showed no nucleotide variants in the two genes. SSCA
and DHPLC indicated the absence of nucleotide changes
in all the LCE3C PCR-fragments. Only one patient
showed an LCE3B heterogeneous SSCA/DHPLC pattern
(Figure 3). After sequencing, we found that this indivi-
dual (a 28 year-old patient with chronic plaque type Ps
without arthritis and heterozygous for the deletion) had
a missense change: R68C (CGC>TGC). We did not find
this nucleotide change in the 400 controls (genotyped
through SSCA).
Discussion
SNP rs4112788 and the LCE3C_LCE3B-del have been
associated with Ps [9,17,20]. In their analysis of 1,425
patients and 1,406 controls from four different popula-
t i o n s ,D eC i de ta l .f o u n das i g n i f i c a n t l yh i g h e rf r e -
quency of del/del homozygotes among the patients
(total del/del frequency, 0.45 in patients vs. 0.34 in con-
trols; OR = 2.04, 95% CI = 1.59-2.62, p = 1.71e-08).
This was further confirmed by Hüffmeier et al. in indivi-
duals of German origin [15]. We did not find this differ-
ence when all the Ps patients were compared to
controls. However, in agreement with these authors the
del/del genotype was more frequent among patients
with psoriasis vulgaris, although our OR was lower and
did not reach statistical significance, probably due to the
limited sample size [9,15].
Huffmeier et al. reported a lack of association between
the LCE3C_LCE3B-del and PsA among German patients
[16]. We found a lower frequency of del/del among the
patients who developed arthritis, compared to patients
with only skin disease. Moreover, when patients with Ps
vulgaris and without joint manifestations were compared
to controls, we found a significantly higher frequency of
the del/del genotype. This confirmed the reported asso-
ciation of this marker with only skin disease [15,16].
Table 2 Genotype and allele frequencies for the
LCE3C_LCE3B-del (parentheses indicate frequencies)
LCE3 genotypes Alleles
II ID DD D I
Controls
(n = 400)
60
(15)
196
(51)
144
(36)
493
(0.61)
307
(0.39)
Total patients
(n = 405)
52
(13)
204
(50)
149
(37)
502
(0.62)
308
(0.38)
Psor. Vulgaris
(n = 324)
30
(9)
157
(49)
137
(42)
431
(0.67)
217
(0.33)
Familial Ps
(n = 221)
32
(14)
113
(51)
76
(34)
265
(0.60)
177
(0.40)
Sporadic Ps
(n = 184)
20
(11)
91
(50)
73
(39)
237
(0.64)
131
(036)
Early onset Ps
(n = 243)
32
(13)
124
(51)
87
(36)
298
(0.61)
188
(0.39)
Late onset Ps
(n = 162)
20
(12)
77
(48)
65
(40)
207
(0.64)
117
(0.36)
Non Severe Ps
(n = 243)
28
(11)
126
(52)
89
(37)
304
(0.63)
182
(0.37)
Severe Ps
(n = 162)
24
(15)
78
(48)
60
(37)
198
(0.61)
126
(0.39)
Arthritis
(n = 83)
8
(10)
49
(59)
26
(31)
101
(0.61)
65
(0.39)
Non arthritis
(n = 322)
44
(14)
155
(45)
123
(41)
401
(0.62)
243
(0.38)
Cw6 positive
(n = 158)
11
(8)
81
(51)
66
(42)
213
(0.67)
103
(0.33)
Cw6 negative
(n = 247)
40
(16)
123
(50)
84
(34)
291
(0.59)
203
(0.41)
Psor. Vulgaris
Non arhritis
(n = 274)
25
(9)
128
(47)
121
(44)
370
(0.68)
178
(0.32)
Coto et al. BMC Medical Genetics 2010, 11:45
http://www.biomedcentral.com/1471-2350/11/45
Page 4 of 7The association between the LCE3C_LCE3B-del and
Ps vulgaris was weaker in our population compared to
the reported by others. This is illustrated by the fact
that for an OR of 1.46 and a p = 0.05 at least 1,154
patients (Ps vulgaris without joint disease) and 938 con-
trols should be genotyped to reach a power of 80. This
discrepancy with other studies could be partly attributed
to differences in the main characteristics of patients and
controls. De Cid et al. analysed a total of 175 patients
and 382 healthy controls from a different Spanish region
[9]. The deletion allele had almost the same frequency
in their patients (0.64) and ours (0.62), and the signifi-
cant risk for Ps was due to a lower frequency of the
deletion among their controls (0.55 vs. 0.61). The lower
association in our study could be thus attributed to dif-
ferences in the criteria followed by the recruitment of
these controls. However, this is unlikely because con-
trols in the two studies were healthy individuals from
the general population and with similar mean age. Mis-
typing of the LCE3C_LCE3B alleles in some of our
patients and controls could also explain the results, but
Figure 2 Taqman genotyping of SNP rs4112788 in 20 individuals, 5 CC (blue dots), 10 CT (green dots), and 5 TT (red dots). The black
spot in the down-left was the negative control.
Figure 3 DHPLC profiles of three LCE3B-PCR fragments.T h e
normal sequences gave a single elution peak, while the fragment
with a nucleotide change eluted as a double peak (B). Fragments
were eluted with the universal gradient of Varian Helix buffers A
and B http://www.varianinc.org/, and at a temperature of 60°C.
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degree of association with rs4112788, a SNP in almost
complete LD with the LCE3C_LCE3B-del. Moreover,
the genotype frequencies in our patients and controls
were in Hardy-Weinberg equilibrium, suggesting they
were representative of the general population.
Differences in the main clinical characteristics of the
patients could also explain the lack of association in
our study. Compared to others, our work included
patients with a higher mean age, and a lower propor-
tion of familial and severe cases. This could explain
the low frequency of Cw6+ among our cases, a marker
reported to be more common among severe early-
onset Ps [21]. The frequency of this marker was also
more frequent among our patients with familial and
early-onset Ps. In this way, the effect of the deletion
allele on Ps-risk could be higher in patients with an
early onset, familial, and severe disease, and this could
result in a reduced frequency of LCE3B_LCE3C-del
among our cases.
Finally, the analysis of LCE3B and LCE3C coding
sequences in cases with at least one copy of these genes
showed that only one patient had a missense change at
ac o n s e r v e dLCE3B amino acid (R68>C). This was not
found in the controls. SSCA and DHPLC are indirect
techniques to detect nucleotide changes in PCR frag-
ments and, although they have a low rate for false nega-
tives, we cannot exclude that some of the patients
harbour non identified mutations.
Conclusions
Our work suggested that individuals homozygous for the
LCE3C_LCE3B-del are at risk of developing Ps vulgaris
without arthritis manifestation. This confirmed the
recently reported association between this marker and
only skin psoriasis, reinforcing the concept of Ps as a
deregulation in the wound response programs.
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